In clinical studies and real-world use, Basal-IQ technology reduces the frequency and duration of lows.

Use of the t:slim X2™ insulin pump with Basal-IQ® technology in a six week PLGS (Predictive Low Glucose Suspend) for Reduction of Low Glucose (PROLOG) Study (n=102) demonstrated a 31% reduction in time spent below 70 mg/dL compared to a sensor-augmented pump (SAP).1 Real-world use of Basal-IQ technology (n=2,712) has demonstrated even greater reductions in time spent low.2

Learn more about THE Real-World Study
Data on real-world use of Basal-IQ technology in Diabetes Technology & Therapeutics >

Time Spent <70 mg/dL (%)

Basal-IQ Time Spent <70 mg/dL (Real-World)
t:slim X2 Insulin Pump with Basal-IQ Technology

Help for patients who can’t recognize when they’re going low.

Basal-IQ predictive low-glucose suspend technology is a simple-to-use system that predicts and helps prevent lows. In the PROLOG pivotal study, the reduction of time spent in low glucose was accomplished without any increase in the rate of hyperglycemia.1

How does Basal-IQ technology work?

Basal-IQ technology uses a simple linear regression algorithm that uses Dexcom G6 CGM values to predict glucose levels 30 minutes ahead based on 3 of the last 4 consecutive CGM readings. If the glucose level is predicted to be less than 80 mg/dL, or if a CGM reading falls below 70 mg/dL, insulin delivery is suspended. Insulin delivery resumes as soon as sensor glucose values begin to rise. Insulin may be suspended for a minimum of 5 minutes and a maximum of 2 hours within a 2.5-hour rolling window.

How Basal-IQ Technology Works

Technology that’s simple to teach and learn can help reduce the training burden on your practice.

Zero Fingersticks

When the t:slim X2 pump is integrated with Dexcom G6 CGM, zero fingersticks are required for calibration or mealtime dosing.

Easy to Use

Responsive Insulin Delivery

Basal-IQ technology can turn insulin delivery on and off as often as every 5 minutes. There is no minimum insulin suspension period. Insulin resumes as soon as sensor glucose values begin to rise.

No Refractory Period

There is no refractory period during which the feature is unavailable. Basal-IQ technology can suspend insulin for up to 2 hours within a 2.5‑hour rolling window.

Operates Silently in the Background

† If glucose alerts and Dexcom G6 CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Responsible Use of Basal-IQ Technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for the active management of diabetes. There are common scenarios in which automated systems cannot prevent a hypoglycemic event. The Basal-IQ feature relies on current CGM sensor readings to function and will not be able to predict glucose levels and suspend insulin delivery if a patient’s CGM is not functioning properly or his/her pump is unable to receive the CGM signal. It’s recommended your patient always uses the components of the pump system (pump, cartridges, CGM, and infusion sets) according to the applicable instructions for use and checks them regularly to make sure they are functioning as expected. Patients should always pay attention to their symptoms, actively monitor and manage glucose levels, and treat according to your recommendations.

* CGM sold separately.
† If glucose alerts and Dexcom G6 CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ Users have the option to request alerts when insulin is suspended and when it resumes. Patients will receive standard CGM alerts and alarms related to low glucose levels that require attention.

1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161.
2. Beck RW, et al. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther.

Important Safety Information

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 insulin pump with Basal-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible integrated continuous glucose monitor (iCGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single patient use. The pump and the System are indicated for use with NovoLog or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit